{"id":167102,"date":"2023-07-08T00:23:49","date_gmt":"2023-07-08T05:23:49","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2023\/07\/fda-grants-accelerated-approval-for-alzheimers-disease-treatment"},"modified":"2023-07-08T00:23:49","modified_gmt":"2023-07-08T05:23:49","slug":"fda-grants-accelerated-approval-for-alzheimers-disease-treatment","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2023\/07\/fda-grants-accelerated-approval-for-alzheimers-disease-treatment","title":{"rendered":"FDA Grants Accelerated Approval for Alzheimer\u2019s Disease Treatment"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/fda-grants-accelerated-approval-for-alzheimers-disease-treatment2.jpg\"><\/a><\/p>\n<p>In January 6 2023, the U.S. Food &amp; Drug Administration approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway for the treatment of Alzheimer\u2019s disease. Leqembi is the second of a new category of medications approved for Alzheimer\u2019s disease that target the fundamental pathophysiology of the disease. These medications represent an important advancement in the ongoing fight to effectively treat Alzheimer\u2019s disease.<\/p>\n<p>Recently it has been granted full approval. Leqembi, developed jointly by Japan\u2019s Eisai and Biogen of the United States, was shown in a clinical trial to modestly reduce cognitive decline among patients in the early stages of the disease.<\/p>\n<p>But the study also raised concerns about side effects including brain bleeds and swelling.<\/p>\n<p>Full approval story.<\/p>\n<p><a href=\"https:\/\/news.cgtn.com\/news\/2023-07-07\/New-Alzheimer-s-drug-gets-full-FDA-approval-1leQ4o7FK0w\/index.html\">https:\/\/news.cgtn.com\/news\/2023-07-07\/New-Alzheimer-\u2026index.html<\/a>.<\/p>\n<p>.<\/p>\n<hr>\n<div class=\"more-link-wrapper\"> <a class=\"more-link\" href=\"https:\/\/lifeboat.com\/blog\/2023\/07\/fda-grants-accelerated-approval-for-alzheimers-disease-treatment\">Continue reading \u201cFDA Grants Accelerated Approval for Alzheimer\u2019s Disease Treatment\u201d | &gt;<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>In January 6 2023, the U.S. Food &amp; Drug Administration approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway for the treatment of Alzheimer\u2019s disease. Leqembi is the second of a new category of medications approved for Alzheimer\u2019s disease that target the fundamental pathophysiology of the disease. These medications represent an important advancement in the ongoing [\u2026]<\/p>\n","protected":false},"author":534,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,1506,47],"tags":[],"class_list":["post-167102","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-food","category-neuroscience"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/167102","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/534"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=167102"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/167102\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=167102"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=167102"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=167102"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}